Biomarkers and Personalized Approach to Cancer Group (BioPAC)

2022 Activity indicators

  • 4 public competitive projects led - ISCIII, MICINN
  • 2 competitive private projects
  • 8 competitive HR contracts
  • 4 publications.
  • IF: 68.01
  • D1 publications: 3 (75 %).
  • Q1 publications: 4 (100 %).
  • Evaluator in public entities: 2 PI
  • Member of editorial committees: 1 PI.
  • 3 hosted visitors and 2 months stay:
    • ULM University (Germany)
    • University College London (United Kingdom)
    • IDIS - Hosp. Clínico Univ. S. de Compostela (Spain)

Milestones

  1. Alonso-Nocelo M., Ruiz-Cañas L.*....Cano A., and Sainz B. Jr. Macrophages direct cancer cells through a LOXL2-mediated metastatic cascade in pancreatic ductal adenocarcinoma. Gut, 2022; 72(2):345-359. FI:31.840  Q1/D1

  2. Frank K.J., ...Sainz B. Jr., Bernards R., Algül H., Lesina M., Mainardi S. Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pancreatic cancer. Cell Reports Medicine, 2022; 3(11):100815. FI:16.988 Q1/D1

  3. CO-IP del Grupo CIBERONC CB16/12/00446 que dirige el Dr. Alfredo Carrato. 

  4. Éxito en concesión ayudas competitivas de RRHH; Juan de la Cierva Formación 2020 (FJC2020-044220-I), Ayudas de la CAM para Técnicos de laboratorio (PEJ-2021-TL/BMD-22441) y un contrato del programa "Yo Investigo". 

  5. Participación como miembros del Equipo del Proyecto  "Selectively eliminating cancer stem cells through inhibition of mitochondrial respiration using metal-based small molecules", La Caixa research Consolidate 2021 (CC21-20122).

Bibliometrics

  Articles Accum. FI Mean FI Articles Q1 or Q2 % in Q1 or Q2 Articles D1 % in D1
2018 7 44,10 7,35 6 86 3 43
2019 6 51,59 8,60 6 100 3 50
2020 11 70,19 6,38 11 100 3 27
2021 9 96,74 10,75 9 100 2 22
2022 4 68,014 17,00 4 100 3 75
  37 330,63 10,02 36 97 14 38

* Only original articles, editorials, guideline and reviews

Networks and alliances